NCT05451849View on ClinicalTrials.gov

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

October 30, 2028

Study Completion Date

October 30, 2028

Conditions
MesotheliomaMesotheliomas PleuralMesothelioma, MalignantMesothelioma PeritoneumOvarian CancerOvarian Serous AdenocarcinomaPancreatic CancerPancreatic AdenocarcinomaColorectal CancerTriple Negative Breast CancerTNBC - Triple-Negative Breast CancerOvarian AdenocarcinomaPancreatic NeoplasmsColorectal NeoplasmsOvarian NeoplasmsCholangiocarcinomaNon Small Cell Lung Cancer
Interventions
BIOLOGICAL

TC-510

TC-510

DRUG

Fludarabine

Fludarabine

DRUG

Cyclophosphamide

Cyclophosphamide

Trial Locations (7)

10461

Montefiore Einstein Cancer Center, The Bronx

20814

National Cancer Institute, Bethesda

33146

University of Miami, Miami

37203

SCRI Oncology Partners, Nashville

55455

University of Minnesota, Masonic Cancer Center, Minneapolis

73104

University of Oklahoma, Oklahoma City

94143

University of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

TCR2 Therapeutics
All Listed Sponsors
lead

TCR2 Therapeutics

INDUSTRY